CellGenix expands HQ to meet increasing demand for GMP cell culture reagents
Strong growth in cell and gene therapy is leading to increased demand for GMP-grade raw materials such as cytokines and serum-free media
CellGenix, a global manufacturing leader of GMP-grade raw materials for cell therapy, gene therapy and tissue-engineered products, has started facility expansions as more customers approach late-stage clinical development and commercialisation.
Early in 2018, the company will add R&D laboratory, production and warehouse space to its German HQ in Freiburg, Germany.
Consequently, there will be new positions in R&D as well as QC and production to fill. The upgrade also introduces state-of-the-art, large scale, filling capacities for recombinant protein products in the existing GMP facilities.
The market forecasts strong growth in cell and gene therapy leading to increased demand for GMP-grade raw materials.
“The investment we are making is a very positive sign for the gene and cell therapy space and the future of CellGenix. It will allow us to fulfill the increasing demand for GMP-grade cytokines and serum-free media. It also shows the importance of high quality GMP reagents for safe, reliable and successful cell and gene therapy manufacturing.” says Prof. Dr Felicia Rosenthal, CEO of CellGenix.